Ing Malcolm R, Hellreich Philip D, Johnson Douglas W, Chen John J
Department of Surgery, University of Hawaii School of Medicine, Honolulu, HI, USA.
Int J Dermatol. 2015 Apr;54(4):476-80. doi: 10.1111/ijd.12385. Epub 2015 Jan 20.
Postherpetic neuralgia remains a therapeutic challenge for the clinician. Many modalities have been utilized with limited success. In this pilot randomized study of patients who were refractory to previous medicinal treatment, the patients were treated with transcutaneous nerve stimulation with a biofeedback capability. After every two treatments with the sham and true device, the patients were required to fill out a standard neuropathic pain scale score. The patients were allowed to select the other device after three consecutive treatments if they felt an inadequate decrease in their pain. The true device was chosen over the sham device by all patients. The majority of these patients treated by the true device reported a statistically significant decrease in pain scores (P < 0.001). Further investigation of this Food and Drug Administration, class 2 accepted, electronic device for relief of pain is warranted for patients with a history of recalcitrant postherpetic neuralgia.
带状疱疹后神经痛对临床医生来说仍是一个治疗挑战。许多治疗方法都曾被采用，但成效有限。在这项针对先前药物治疗无效的患者的初步随机研究中，患者接受了具有生物反馈功能的经皮神经刺激治疗。在使用假装置和真装置各进行两次治疗后，患者需要填写一份标准的神经性疼痛量表评分。如果患者感觉疼痛减轻不明显，在连续三次治疗后可选择使用另一种装置。所有患者都选择了真装置而非假装置。接受真装置治疗的这些患者中，大多数报告疼痛评分有统计学意义的下降（P < 0.001）。对于有顽固性带状疱疹后神经痛病史的患者，有必要对这种已获美国食品药品监督管理局二类认可的缓解疼痛的电子装置作进一步研究。
